Kenvue Inc. reported fiscal second quarter results ending June 28, 2026, with net sales increasing 3.0% to $3.955 billion and diluted earnings per share rising 9% to $0.24. The company delivered its third consecutive quarter of organic sales growth, driven by favorable value realization and volume increases across Self Care, Skin Health and Beauty, and Essential Health segments. Kenvue received FDA approval for Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium. The company will not provide forward-looking guidance or host a conference call due to its pending merger with Kimberly-Clark, which is expected to close in the fourth quarter of 2026 subject to foreign regulatory approvals. Kenvue Inc. operates as a global consumer health company producing over-the-counter medications and personal care products.

Kenvue Inc. has released its financial results for the first fiscal quarter ended March 29, 2026. This announcement is a critical update for investors to assess the company's recent operational performance and financial health.